Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer

N. Panupinthu, S. Yu, Dong Zhang, F. Zhang, M. Gagea, Y. Lu, J. R. Grandis, S. E. Dunn, H. Y. Lee, Gordon Mills

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The Y-box binding protein-1 (YB-1) transcription factor is associated with unfavorable clinical outcomes. However, the mechanisms underlying this association remain to be fully elucidated. We demonstrate that YB-1 phosphorylation, indicative of YB-1 activation, is a powerful marker of outcomes for ovarian cancer patients. In ovarian cancer, YB-1 phosphorylation is induced by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Activation of the LPAR/SRC/EGFR/MAPK/p90RSK/YB-1 axis leads to production of the EGFR ligand amphiregulin (AREG). AREG induces ongoing YB-1 phosphorylation as well as YB-1-dependent AREG expression, thus constituting an AREG/YB-1 self-reinforcing loop. Disruption of transactivation of the EGFR and the downstream self-reinforcing loop decreases invasiveness of ovarian cancer cells in vitro and limits ovarian cancer growth in xenograft models. These findings established the regulation and significance of YB-1 phosphorylation, therefore further exploration of this signaling axis as a therapeutic avenue in ovarian cancer is warranted.

Original languageEnglish (US)
Pages (from-to)2846-2856
Number of pages11
JournalOncogene
Volume33
Issue number22
DOIs
StatePublished - May 29 2014
Externally publishedYes

Fingerprint

Y-Box-Binding Protein 1
Ovarian Neoplasms
Epidermal Growth Factor Receptor
90-kDa Ribosomal Protein S6 Kinases
Lysophosphatidic Acid Receptors
Phosphorylation
Transcriptional Activation
Phosphatidylinositol 3-Kinase
Heterografts
Transcription Factors
Amphiregulin
Ligands
Growth

Keywords

  • autoregulation
  • crosstalk
  • feedback
  • G-protein-coupled receptor
  • receptor tyrosine kinase

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. / Panupinthu, N.; Yu, S.; Zhang, Dong; Zhang, F.; Gagea, M.; Lu, Y.; Grandis, J. R.; Dunn, S. E.; Lee, H. Y.; Mills, Gordon.

In: Oncogene, Vol. 33, No. 22, 29.05.2014, p. 2846-2856.

Research output: Contribution to journalArticle

Panupinthu, N, Yu, S, Zhang, D, Zhang, F, Gagea, M, Lu, Y, Grandis, JR, Dunn, SE, Lee, HY & Mills, G 2014, 'Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer', Oncogene, vol. 33, no. 22, pp. 2846-2856. https://doi.org/10.1038/onc.2013.259
Panupinthu, N. ; Yu, S. ; Zhang, Dong ; Zhang, F. ; Gagea, M. ; Lu, Y. ; Grandis, J. R. ; Dunn, S. E. ; Lee, H. Y. ; Mills, Gordon. / Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. In: Oncogene. 2014 ; Vol. 33, No. 22. pp. 2846-2856.
@article{7ffb4f66d785486d89e62f57d40b4d06,
title = "Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer",
abstract = "The Y-box binding protein-1 (YB-1) transcription factor is associated with unfavorable clinical outcomes. However, the mechanisms underlying this association remain to be fully elucidated. We demonstrate that YB-1 phosphorylation, indicative of YB-1 activation, is a powerful marker of outcomes for ovarian cancer patients. In ovarian cancer, YB-1 phosphorylation is induced by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Activation of the LPAR/SRC/EGFR/MAPK/p90RSK/YB-1 axis leads to production of the EGFR ligand amphiregulin (AREG). AREG induces ongoing YB-1 phosphorylation as well as YB-1-dependent AREG expression, thus constituting an AREG/YB-1 self-reinforcing loop. Disruption of transactivation of the EGFR and the downstream self-reinforcing loop decreases invasiveness of ovarian cancer cells in vitro and limits ovarian cancer growth in xenograft models. These findings established the regulation and significance of YB-1 phosphorylation, therefore further exploration of this signaling axis as a therapeutic avenue in ovarian cancer is warranted.",
keywords = "autoregulation, crosstalk, feedback, G-protein-coupled receptor, receptor tyrosine kinase",
author = "N. Panupinthu and S. Yu and Dong Zhang and F. Zhang and M. Gagea and Y. Lu and Grandis, {J. R.} and Dunn, {S. E.} and Lee, {H. Y.} and Gordon Mills",
year = "2014",
month = "5",
day = "29",
doi = "10.1038/onc.2013.259",
language = "English (US)",
volume = "33",
pages = "2846--2856",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "22",

}

TY - JOUR

T1 - Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer

AU - Panupinthu, N.

AU - Yu, S.

AU - Zhang, Dong

AU - Zhang, F.

AU - Gagea, M.

AU - Lu, Y.

AU - Grandis, J. R.

AU - Dunn, S. E.

AU - Lee, H. Y.

AU - Mills, Gordon

PY - 2014/5/29

Y1 - 2014/5/29

N2 - The Y-box binding protein-1 (YB-1) transcription factor is associated with unfavorable clinical outcomes. However, the mechanisms underlying this association remain to be fully elucidated. We demonstrate that YB-1 phosphorylation, indicative of YB-1 activation, is a powerful marker of outcomes for ovarian cancer patients. In ovarian cancer, YB-1 phosphorylation is induced by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Activation of the LPAR/SRC/EGFR/MAPK/p90RSK/YB-1 axis leads to production of the EGFR ligand amphiregulin (AREG). AREG induces ongoing YB-1 phosphorylation as well as YB-1-dependent AREG expression, thus constituting an AREG/YB-1 self-reinforcing loop. Disruption of transactivation of the EGFR and the downstream self-reinforcing loop decreases invasiveness of ovarian cancer cells in vitro and limits ovarian cancer growth in xenograft models. These findings established the regulation and significance of YB-1 phosphorylation, therefore further exploration of this signaling axis as a therapeutic avenue in ovarian cancer is warranted.

AB - The Y-box binding protein-1 (YB-1) transcription factor is associated with unfavorable clinical outcomes. However, the mechanisms underlying this association remain to be fully elucidated. We demonstrate that YB-1 phosphorylation, indicative of YB-1 activation, is a powerful marker of outcomes for ovarian cancer patients. In ovarian cancer, YB-1 phosphorylation is induced by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Activation of the LPAR/SRC/EGFR/MAPK/p90RSK/YB-1 axis leads to production of the EGFR ligand amphiregulin (AREG). AREG induces ongoing YB-1 phosphorylation as well as YB-1-dependent AREG expression, thus constituting an AREG/YB-1 self-reinforcing loop. Disruption of transactivation of the EGFR and the downstream self-reinforcing loop decreases invasiveness of ovarian cancer cells in vitro and limits ovarian cancer growth in xenograft models. These findings established the regulation and significance of YB-1 phosphorylation, therefore further exploration of this signaling axis as a therapeutic avenue in ovarian cancer is warranted.

KW - autoregulation

KW - crosstalk

KW - feedback

KW - G-protein-coupled receptor

KW - receptor tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84901818936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901818936&partnerID=8YFLogxK

U2 - 10.1038/onc.2013.259

DO - 10.1038/onc.2013.259

M3 - Article

C2 - 23851501

AN - SCOPUS:84901818936

VL - 33

SP - 2846

EP - 2856

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 22

ER -